Request Demo
Last update 13 Jan 2026
JSKN016
Last update 13 Jan 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms JSKN016 |
Target |
Action modulators, inhibitors |
Mechanism HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
7
Clinical Trials associated with JSKN016CTR20251595
评估JSKN016联合治疗在不可手术切除局部晚期或转移性HER2阴性乳腺癌参与者中的疗效和安全性的临床研究
[Translation] A clinical study to evaluate the efficacy and safety of JSKN016 combination therapy in participants with unresectable locally advanced or metastatic HER2-negative breast cancer
NCT06942234
The Multicenter, Open-label, Single-arm, Multi-cohort Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of JSKN016 in Combination Therapy in Chinese Participants With Inoperable Locally Advanced or Metastatic HER2-negative Breast Cancer
NCT06868732
Evaluation of JSKN016 Combination Therapy in Subjects with Advanced Non-Small Cell Lung Cancer: a Phase Ib Study
100 Clinical Results associated with JSKN016
Login to view more data
100 Translational Medicine associated with JSKN016
Login to view more data
100 Patents (Medical) associated with JSKN016
Login to view more data
1
Literatures (Medical) associated with JSKN016RSC Medicinal Chemistry
Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates
Review
Author: Liu, Yunpeng ; Yang, Qiang
Fc-glycan-specific ADC is a significant advance in site-specific ADCs for cancer therapy. Notably, JSKN003 and IBI343 have demonstrated promising results in phase 1 clinical trials and are advancing into phase 3 studies.
100 Deals associated with JSKN016
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hormone receptor positive HER2 negative breast cancer | Phase 2 | China | 01 Jan 2026 | |
| Locally advanced breast cancer | Phase 2 | China | 01 Jan 2026 | |
| Metastatic breast cancer | Phase 2 | China | 01 Jan 2026 | |
| HER2-negative breast cancer | Phase 2 | China | 01 Jun 2025 | |
| Metastatic HER2-Negative Breast Carcinoma | Phase 2 | China | 01 Jun 2025 | |
| Adenocarcinoma of Esophagus | Phase 2 | China | 25 Apr 2025 | |
| Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 | China | 25 Apr 2025 | |
| stomach adenocarcinoma | Phase 2 | China | 25 Apr 2025 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | - | 17 Jan 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 2 | China | 13 Jan 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | HER2-negative breast cancer HER2-negative | 82 | ewbsaeykvb(hipryqivys) = wfybvceggf qfvgdsnemh (gvygdqiyhi, 66.3 - 94.5) View more | Positive | 10 Dec 2025 | ||
mrcasssxih(ijnbcvzrdz) = qcwvknbogf ohgxdjknxt (cktxgbrsxw ) View more | |||||||
Phase 1 | Metastatic Triple-Negative Breast Carcinoma TROP2 | HER3 | 19 | gpzrizzsxa(gviczsqmom) = Manageable hemotoxicity was observed with ≥ G3 events only occurred in 2 (10.5%) pts, including 1 G3 neutropenia and 1 G3 lymphopenia cuuuphxkct (gogbynaxnk ) View more | Positive | 30 May 2025 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free